{"id":139348,"title":"ValiRx Secures Second European Patent for Cytolytix Cancer-Killing Peptide","publisher":"Share Talk","author":"sharetalk","published":"2026-08-10T09:39:33+00:00","modified":"2026-08-10T10:44:00+00:00","canonical_url":"https://www.share-talk.com/valirx-secures-second-european-patent-for-cytolytix-cancer-killing-peptide/","markdown_url":"https://www.share-talk.com/valirx-secures-second-european-patent-for-cytolytix-cancer-killing-peptide.md","json_url":"https://www.share-talk.com/valirx-secures-second-european-patent-for-cytolytix-cancer-killing-peptide.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Black Cat Bio","collaboration","coronavirus","Dr Patrick Frankham","Dr Suzy Dilly","Drug Discovery Technologies","GeneICE","Mark Eccleston","Oncolytika Limited","Patent","Share Talk","Suzanne Dilly","TheoremRx","VAL","ValiRx"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/08/db0fde47-0a61-44bd-bcac-65189a06d7de.png?fit=1727%2C911&ssl=1","format":"news","language":"en-GB","content":"[ValiRx PLC (AIM: VAL)](https://www.investegate.co.uk/announcement/rns/valirx--val/cytolytix-patent-update/9711872) has received notice that the European Patent Office intends to grant a second patent covering the cancer-killing peptide being developed by its majority-owned subsidiary **Cytolytix**.\n\nThe patent covers **polyleucine-based peptides as anti-cancer agents** and follows the grant in May of a separate European patent protecting the nanoparticle formulation used to deliver the peptide.\n\nThe expanded patent protection strengthens Cytolytix’s intellectual property position as ValiRx pursues **licensing, pharmaceutical partnerships and non-dilutive funding**.\n\nCytolytix’s technology works by disrupting cancer cell membranes, directly killing tumour cells while releasing antigens that may stimulate an immune response. Its lead target is **triple-negative breast cancer**, an aggressive cancer with limited targeted treatment options.\n\nValiRx has also filed a further patent application covering a second-generation lipid-based delivery system, supported by data demonstrating immunogenic cell death in triple-negative breast cancer cells.\n\nChief Executive **Mark Eccleston** said the growing range of proprietary formulations could enable different routes of administration across both human and veterinary cancer markets."}